New Publication in Blood: Single-cell MRD reveals AML patients benefiting from CXCR4 inhibition
CRC 1709 postdoctoral researcher Enise Ceran is the first author of a new study published in Blood, demonstrating how single-cell measurable residual disease (scMRD) profiling can identify patients with acute myeloid leukemia (AML) who are most likely to benefit from…












